Sweden's Cantargia 2025 sales rise but miss analyst expectations

Cantargia AB

20/02/2026 06:10

Overview

Sweden's biotechnology firm reported 2025 net sales of SEK 316.7 mln, missing expectations

EPS for 2025 was SEK 0.59

Company highlighted FDA Fast Track Designation and Otsuka partnership as significant events

Outlook

Cantargia expects to advance nadunolimab towards market entry in 2026

Result Drivers

FINANCIAL IMPROVEMENT - Operating results improved significantly, with net sales increasing to SEK 316.7 mln

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Miss
SEK 316.70 mln
SEK 321.40 mln (3 Analysts)
FY EPS
SEK 0.59


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Cantargia AB is SEK6.25, about 23.8% above its February 19 closing price of SEK5.05

Press Release: ID:nMFN20vPk0

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)